AUTIFONY THERAPEUTICS LIMITED - Profile & Financials

Accounts Submitted 13 Jun 2025

Confirmation Statement Submitted 4 Mar 2025

Net assets £16.35M £10.73M 2024 year on year

Total assets £18.48M £11.37M 2024 year on year

Total Liabilities £2.13M £636.27K 2024 year on year

Charges 1

1 satisfied

AI Analysis

Analyze director networks, ownership patterns, and company connections

CompanyTrack AI can make mistakes. Check important info.

Contact & Details

Contact

Update Details

Registered Address

Stevenage Bioscience Catalyst Gunnels Wood Road Stevenage Hertfordshire SG1 2FX England

Office ()

London, England, United Kingdom, Europe

info@autifony.com

Website

autifony.com

Credit Report

Discover AUTIFONY THERAPEUTICS LIMITED's Credit Score, limit, and payment likelihood.

Mutual Companies

See All Mutual Companies

Financials

Period 1 Jan → 31 Dec 2024

Type Total Exemption Full

Next accounts 31 December 2025

Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2015–2024)

Cash in Bank

£14.74M

Increased by £10.23M (+227%)

Net Assets

£16.35M

Increased by £10.73M (+191%)

Total Liabilities

£2.13M

Increased by £636.27k (+43%)

Turnover

£19.32M

Increased by £17.95M (+1310%)

Employees

N/A

Decreased by 24 (-100%)

Debt Ratio

12%

Decreased by 9 (-43%)

Financial History

Revenue, profit, EBITDA and key financial figures

	2024 Dec Year End	2023 Dec Year End
P&L
Revenue	£142.3M	£128.7M
Gross Profit	£48.2M	£43.1M
Operating Profit	£22.4M	£19.8M
Net Profit	£18.1M	£15.9M
EBITDA	£31.5M	£28.2M
Assets
Cash	£24.7M	£21.3M
Total Assets	£89.4M	£82.1M
Liabilities
Total Liabilities	£45.2M	£41.8M
Key Metrics
Employees	1,247	1,156

Latest Revenue

£142.3M

Latest EBITDA

£31.5M

Cash Position

£24.7M

Funding

Fundraising & Grants

£38.1m raised

Show:

Investors (10)

Investor Name	Investor Since	Participating Rounds
SV Life Sciences	Aug 2011	Series A Extension, Series A
Imperial Innovations	Aug 2011	Series A Extension, Series A
Pfizer Venture Investments	Aug 2011	Series A Extension, Series A

Share Capital

Share allotments and capital structure

12 Allotments 1,753,562 Shares £628k Total

Date From	Share Class	Shares Allotted	Amount Raised	Price/Share
29 Jul 2024	B ORDINARY	1,000	£1k	£1.2
29 Jul 2024	ORDINARY	45,000	£45	£0.001
26 Feb 2024	ORDINARY	325,000	£325	£0.001
23 Nov 2023	ORDINARY	25,000	£625k	£25
12 Oct 2023	ORDINARY	30,000	£30	£0.001

Officers

6 active 10 resigned

Show resigned officers

						Status
Catherine Elizabeth Bingham	Director	British	England	60	19 Aug 2011	Active
Charles Henry Large	Director	British	England	58	23 May 2011	Active
Hannah Louise Selin	Secretary	Unknown	Unknown	—	7 May 2025	Active
Ip2ipo Services Limited	Corporate-director	United Kingdom	Unknown	—	12 Mar 2018	Active
John Edward Berriman	Director	British	England	77	23 May 2011	Active
Rana Al-hallaq	Director	American	United States	50	15 Apr 2019	Active

Shareholders

Shareholders (99)


Wendy Kennedy	0.0%	5,785	Ordinary	4 Mar 2025
Wendy Kennedy	0.0%	90	B Ordinary	4 Mar 2025
Xperimed Gmbh	0.0%	45	B Ordinary	4 Mar 2025

Persons with Significant Control

Persons with Significant Control (1)

1 Active 2 Ceased

Touchstone Innovations Businesses Llp

United Kingdom

Active

Notified 6 Apr 2016

Nature of Control

Ownership Of Shares 25 To 50 Percent
Voting Rights 25 To 50 Percent

Pfizer Inc

Ceased 12 Jan 2023

Ceased

Svls Life Sciences Fund V Lp

Ceased 1 Nov 2021

Ceased

See All Controllers

Group Structure

TOUCHSTONE INNOVATIONS BUSINESSES LLP united kingdom right to share surplus assets 75 to 100 percent limited liability partnership

IP2IPO INNOVATIONS LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent, appoint/remove directors

TOUCHSTONE INNOVATIONS LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent, appoint/remove directors

IP GROUP PLC united kingdom

AUTIFONY THERAPEUTICS LIMITED Current Company

AUTIFONY ALPHA LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent, appoint/remove directors

Charges

1 satisfied

Documents

Company Filings

Date	Category	Description	Document
17 Oct 2025	Capital	Statement by Directors	View(6 pages)
17 Oct 2025	Insolvency	Solvency Statement dated 03/10/25	View(6 pages)
17 Oct 2025	Capital	Capital Statement Capital Company With Date Currency Figure	View(12 pages)
17 Oct 2025	Resolution	Resolutions	View(13 pages)
13 Jun 2025	Accounts	Annual accounts made up to 2024-09-30	View(39 pages)